Company / SG&A Expense
Celularity Inc SG&A Expense History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$51.3M
FY2025
5-year range
$50.6M / $71.3M
FY2021-FY2025
Trend
-12.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
$51M in FY2025 with a 3-year CAGR of -8.1%.
Remained stable around $51M over the past 2 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -8.1%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -8.1%, indicating a declining trend.
- In FY2025, sg&a expense decreased 12.6% year-over-year.
- Peak sg&a expense was recorded in FY2021.
- Lowest sg&a expense in the period was in FY2023.
Company context
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -9.92 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $51.3M | -12.6% |
| FY2024 | $58.6M | +16.0% |
| FY2023 | $50.6M | -23.4% |
| FY2022 | $66.0M | -7.5% |
| FY2021 | $71.3M | - |
As of FY2025 · SEC 10-K · Updated Jun 29, 2026